Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
It also empowers domestic precision immunotherapy for tumours and promotes the high-quality development of China's biopharmaceutical industry
The three prequalified products are manufactured by the originator company, Roche, but the listings should pave the way for more companies coming forward to seek WHO prequalification
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions
LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment
This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
Subscribe To Our Newsletter & Stay Updated